BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
2.820
-0.130 (-4.41%)
Oct 16, 2026, 4:00 PM EDT - Market closed
BBOT's stock price has decreased by -76.4% in the past year and price targets may not have had time to catch up.
BBOT Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Reiterates $27 → $25 | Buy | Reiterates | $27 → $25 | +786.52% | Sep 18, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 15, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $25 | Buy | Maintains | $25 | +786.52% | Sep 9, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $21 | Buy | Maintains | $21 | +644.68% | Sep 9, 2026 |
| Raymond James | Raymond James | Buy Maintains $24 → $22 | Buy | Maintains | $24 → $22 | +680.14% | Sep 9, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $23 → $15 | Buy | Maintains | $23 → $15 | +431.91% | Sep 9, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $23 → $20 | Buy | Maintains | $23 → $20 | +609.22% | Sep 9, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $18 | Buy | Reiterates | $18 | +538.30% | Aug 17, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.